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Abstract 
Background and aims: The miRNA expression profiles of the terminal ileum, sigmoid colon, and rectal 
mucosa of adult patients with active Crohn’s disease (CD) have been previously reported. The purpose of 
this study was to identify dysregulated miRNAs in the mucosa of the ascending colon. 
Methods: Biopsy tissue samples were taken from the mucosae of inflammatory (iCD) or 
non-inflammatory (niCD) areas of the ascending colons of adult patients with active CD. miRNA and 
mRNA expression profiles were detected using microarray analyses. miRNAs and mRNAs demonstrating 
significant differences were validated via quantitative real-time PCR (qRT-PCR). Luciferase reporter 
genes were used to measure two miRNAs inhibition of potential target genes in human 293T cells in vitro. 
Results: Compared with the HC group, the ascending colon miRNA expression profiles revealed that 43 
miRNAs were significantly up-regulated and 35 were down-regulated in the iCD group. The mRNA 
expression profiles indicated that 3,370 transcripts were significantly differentially expressed in the 
ascending colon, with 2169 up-regulated and 1201 down-regulated mRNAs in the iCD group, and only 20 
miRNAs demonstrated significant differential expression in the niCD group. In contrast, nearly 100 
miRNAs significantly varied between the iCD and niCD groups. Finally, luciferase reporter gene assays 
showed that hsa-miR-16-1 directly regulated the human C10orf54 gene and that they were negatively 
correlated. 
Conclusions: Our results indicated that the differentially expressed miRNAs and mRNAs were related to 
immune inflammation and intestinal flora. The data provide preliminary evidence that the occurrence of 
CD involves the inhibition of C10orf54 expression by hsa-miR-16-1.  
Key Words: Crohn’s disease; ascending colon mucosa; microRNA expression profiles; mRNAs  
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Introduction 
 Inflammatory bowel disease (IBD) is an intestinal inflammatory disease characterized by chronic 
nature, and tendency to relapse. CD has a long and persistent disease duration, is recurrent, and can 
seriously affect the quality of life of patients. Therefore, CD has been designated by the World Health 
Organization (WHO) as an intractable digestive disease. In Europe, there are approximately 2.5-3 
million IBD patients, costing approximately €4.6-5.6 billion in healthcare spending each year 1. The 
general clinical symptoms of Chinese patients are relatively mild: there are fewer incidences of 
symptoms outside of the intestine as well as fewer complications, and fistula and perianal 
complications are rare 
2
. However, with the recent improvement of China's GDP and quality of life, 
the incidence of CD clearly trended upward, the age of onset has tended to be younger 
2
, and familial 
aggregation has become less significant 
3
. Although it is currently considered that the pathogenesis 
and development of CD is closely related to interactions between the internal and external 
environments of the body, susceptibility genes, and immunomodulatory factors, the precise 
pathogenic mechanism remains unclear 
4, 5
. 
 In the past 20 years, international collaboration via genome-wide association studies (GWAS) 
investigated potential IBD pathogenic genes. In these studies, CD occurrence was closely related to 
autophagy and immunity 
6
. miRNAs are small non-coding RNAs (21-23 nucleotides in length) that 
bind to specific target mRNAs, thereby post-transcriptionally inhibiting gene expression 
7, 8
. Although 
the biological functions of only a small portion of the miRNAs have been elucidated, their importance 
is exemplified by roles in the regulation of gene expression, the cell cycle, and development as well as 
in immune response regulation 
7, 9
. miRNA binding sites are often located in the 3' untranslated region 
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(UTR) of a target mRNA transcript, leading to mRNA degradation or translational inhibition. An 
increasing number of studies have focused on miRNA function in the intestinal immune system: these 
results provide evidence that miRNAs can regulate intestinal epithelial tight junction permeability 
10
 
and T helper cell (Th)-17-mediated inflammation and autophagy 
11, 12
. Second-generation sequencing 
methods have been applied to active CD patient samples versus healthy control groups to measure 
differential miRNA expression profiles in the peripheral blood and inflammatory and 
non-inflammatory areas of intestinal tissues 
13, 14
. However, few studies have focused on miRNA 
expression in the mucosae of affected areas (the terminal ileum, sigmoid colon, and rectum) in active 
CD patients 
15-17
, the ascending colon and the terminal ileum are the most common sites of CD 
18
, 
protein biomarkers of ascending colon biopsies may differentiate Crohn’s disease from UC 
throughout proteomic analysis 
19
, and no reports have investigated miRNA mechanisms from the 
perspective of the ascending colon mucosa of CD patients. Hence, the miRNA expression profile 
characteristics of the ascending colon mucosa remain unclear. 
 The goal of this study was to observe whether miRNA expression profiles were altered in the 
ascending colon mucosa of active CD patients and if these profiles differed between mucosa 
originating from inflammatory and non-inflammatory regions. We further sought to identify 
differentially expressed mRNAs in inflammatory ascending colon mucosae from CD patients.  
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Materials and Methods 
Subjects and ascending colon tissue collection 
 Adult patients were come from the CD specialty department at the Shanghai Institute of 
Acupuncture and Meridian and Zhongshan Hospital of Fudan University from July 2009 to May 2010. 
All patients were type L2B1 (colonic, non-stricturing, non-penetrating) and were enrolled according 
to the Montreal classification criteria 
20
. Patients were evaluated using the Crohn's Disease Activity 
Index (CDAI), and all enrolled patients had CDAI scores greater than 150 points. A portion of biopsy 
specimens were from ascending colon regions with inflammation (CD, ulcer surface, three 
biopsies/area), and the others were from normal regions (CD, 8 cm above the inflammatory mucosa, 
three biopsies/area). Healthy volunteers who were screened and provided colon biopsies were 
designated the healthy control (HC) group. HC and CD biopsy specimens were collected into 
pre-labelled cryopreservation vials, immediately soaked in liquid nitrogen, and stored at -80 ºC until 
testing. All patients and healthy volunteers were from a randomized controlled clinical trial (Clinical 
Trial Registration: ChiCTR-TRC-10000950), which was approved by the Ethics Committee of the 
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine in affiliation with the 
Shanghai University of Traditional Chinese Medicine (No: 2009-02); all subjects provided informed 
consent. The methods were carried out in accordance with the approved guidelines 
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RNA extraction and quality control 
 TRIzol reagent (Invitrogen, Carlsbad, CA, USA) was used to extract total RNA from the biopsy 
samples. The miRNeasy mini kit (QIAGEN, Hilden, Germany) was also used for miRNA separation 
and purification. A NanoDrop (ND-1000; NanoDrop Technologies, Wilmington, DE, USA) was used 
for quality determination and quantification of total RNA, and RNA integrity was observed following 
1% agarose gel electrophoresis. The Agilent 2100 (Agilent Technologies, Palo Alto, CA, USA) was 
used for quality control. Total RNA samples with an RNA integrity number (RIN) greater than 7 were 
used for microarray analysis.  
miRNA microarray analysis 
 Shanghai KangChen Bio-tech measured the miRNA expression profiles of the ascending colon 
mucosa samples using the miRCURY
TM
 LNA Array (v.16.0, Exiqon, Vedbaek, Denmark). The 
miRNA hybridization method was based on the procedures provided with the miRCURY LNA. RNA 
samples were labelled with Hy3 fluorescence using the miRCURY
TM
 array labelling kit (Exiqon, 
Vedbaek, Denmark). Fluorescence-labelled miRNAs were identified after hybridization by 
sequencing. The hybridized miRNAs were washed using the buffer kit (Exiqon, Vedbaek, Denmark), 
dried, and scanned using a GenePix 4000B array scanner (Molecular Devices, Sunnyvale, CA, USA). 
Gene microarray analysis  
 Total RNA from each group was reverse transcribed into cDNA then labelled with Cy3. The 
labelled cDNA samples were hybridized with Homo sapiens arrays (Roche NimbleGen, No. 
05543789001) containing 45,034 human genes. A GenePix 4000B microarray scanner scanned the 
  
This article is protected by copyright. All rights reserved. 
monochromatic NimbleGen arrays, and GenePix Pro V6.0 was used to read the original image pixel. 
Details of the labelling, hybridization, scanning, and standardization are as described on the 
NimbleGen website (http://www.nimblegen.com). The standardized values were analysed using the 
online sequence analysis system GeneSifter (http://www.genesifter.net). 
miRNA and mRNA real-time quantitative PCR validation 
 The miRNA and mRNA microarray results were verified via quantitative real-time PCR 
(qRT-PCR) of miRNA and mRNA expression in each group of ascending colon mucosal tissues. 
cDNA was synthesized in the presence of a dNTP mixture (HyTest, Turku, Finland) and MMLV 
reverse transcriptase (Epicentre, Madison, WI, USA) using the Gene Amp PCR System 9700 
(Applied Biosystems). qRT-PCR was then conducted using the ABI PRISM 7900 system (Applied 
Biosystems) with the following program: 95 ºC, 10 min; 40 cycles of 95 ºC, 10 sec and 60 ºC, 60 sec. 
The relative expression levels of miRNA and mRNA were normalized to U6 (a ubiquitous small 
nuclear RNA) and GAPDH, respectively, and calculated using the 2
-△△Ct
 method. Primers for miRNA 
and mRNA are listed in Table S5. 
miRNA target gene prediction  
 For miRNAs that were differentially expressed between the iCD and HC groups, target genes 
were scored and screened by combining the algorithms of TargetScan (http://www.targetscan.org), 
miRBase (http://www.mirbase.org), and miRWalk (http://www.ma.uni-heidelberg.de/apps/zmf/ 
mirwalk/). 
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Luciferase reporter assays  
Mutated 3’UTR gene sequences were inserted into the XbaI and FseI sites of the pGL3 vector 
(Genechem, Shanghai, China). HEK293T cells transfected with miRNA mimics (RiboBio, Guangzhou, 
China) or a negative control were seeded into 24-well plates. The pGL3 vector (0.1 μg) with the inserted 
3’UTR sequence was cotransfected with the pRL-TK vector (0.02 μg) using X-treme GENE HP (Roche). 
After 24 hours, the cells were harvested according to the manufacturer’s protocol (Promega Corporation, 
Fitchburg, Wisconsin, USA) and firefly and Renilla luciferase activities were detected using the 
Dual-Luciferase Reporter Assay System (Promega Corporation, Fitchburg, Wisconsin, USA) with a Tecan 
Infinite reader. Taget genes and sequence of hsa-miR-16-1 and hsa-miR-142-3p were shown in Table S6. 
Data analysis 
 miRNAs with significant differences in expression were normalized using the double-filtering 
criteria: adjusted P-value (FDR) < 0.05 and absolute log2 fold change (absolute log2FC) > 1. Pathway 
and GO analyses, cluster analysis (Cluster 3.0) and TreeView analysis (Stanford University, Stanford, 
CA, USA) were applied to the results. miRNA and mRNA expression differences were detected and 
tested using Kruskal-Wallis and Holm-Bonferroni post-hoc tests 
21
. Measurement data are expressed 
as the means ± standard deviation, and comparisons between two groups were conducted using 
independent sample t-tests (SPSS17.0, Chicago, IL). Figures were plotted using Graphpad Prism 5 
(San Diego, CA, USA). P values of < 0.05 were indicative of statistically significant differences.
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Results 
 A comprehensive summary of sample information is listed in Table S1. CD samples were 
divided into ascending colon mucosal samples with inflammation (iCD) or without inflammation 
(niCD). The total number of samples included 7 iCD, 7 niCD, and 7 healthy controls. Overall, 
intestinal mucosa samples (from 14 individuals: seven CD patients and seven healthy volunteers) 
were obtained (Figure 1A). Specific sample information, including ethnic background, CDAI, 
previous treatments, and other clinical data, is listed in Table S2. Morphological observation of the 
patient intestinal mucosal tissues is shown in Figure S1. Figure S1A shows that in the HC group, the 
epithelium was intact, with no ulcerations. The intestinal glands were arranged in an orderly manner 
in the lamina propria. Figure S1B shows that in the iCD group, the mucosal epithelium was damaged, 
with ulcerations and obvious hemorrhage. The intestinal glands were reduced in size. In addition, 
there was substantial lymphocytic cell infiltration in the intestinal mucosa and submucosa. Figure S1C 
shows that in the niCD group, there was a small amount of hyperemia and inflammatory cell 
infiltration in the intestinal mucosa and submucosa. The intestinal glands were arranged in an orderly 
manner. 
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Overlaps in miRNAs differentially expressed between inflammatory and non-inflammatory 
CD mucosae 
 The iCD and HC groups had eight differentially expressed miRNAs in common with the niCD 
and HC groups and 45 overlaps with the iCD and niCD groups; the niCD and HC groups had five 
differentially expressed miRNAs in common with the iCD and niCD groups, and the three groups had 
only one common overlap, hsa-miR-223 (Figure 1B). We compared the expression of the four most 
significantly upregulated miRNAs (with defined names) (miR-144, miR-451, miR-31, and 
miR-142-3p) and the four most significantly downregulated miRNAs (miR-1973, miR-1205, 
miR-5481 and miR-491-3p) in iCD samples compared to HC samples. In inflammatory colonic 
mucosae of CD patients, miR-144, miR-451, miR-31, and miR-142-3p demonstrated significantly 
higher expression levels than in healthy colonic mucosae or non-inflamed areas, where the expression 
levels of these four miRNAs were similar (Figure 1C). In contrast, the expression levels of miR-1973, 
miR-1205, miR-5481, and miR-491-3p were significantly reduced in the inflammatory colonic 
mucosae of CD patients relative to healthy colonic mucosae. The expression of miR-1205 was 
reduced in both inflammatory and non-inflammatory areas; however, the expression levels of 
miR-1973, miR-5481, and miR-491-3p in non-inflammatory areas were similar to those of healthy 
tissues (Figure 1D). 
miRNA expression profiles change in inflammatory ascending colon mucosa  
We found that the miRNA expression profile in the ascending colon mucosae differed 
significantly between the iCD and HC groups. Of the 1257 miRNA detected, 78 miRNAs differed 
significantly between the iCD and HC groups (P < 0.05, FDR < 0.05), with 43 miRNAs upregulated 
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and 35 downregulated (Figure 1B, Figure 2B). The heat map of differentially expressed miRNAs 
suggests that the CD group of samples differed from the HC group (Figure 2A). 
miRNA expression profile changes in non-inflammatory ascending colon mucosae  
Our microarray analysis demonstrated that, compared with the HC group, two miRNAs were 
upregulated and 18 miRNAs were downregulated in the non-inflammatory ascending colon mucosae 
of CD patients (Figure 1B, Figure 3B). Cluster analyses of the differentially expressed miRNAs 
suggest differences between samples from the niCD group and those from the HC group (Figure 3A). 
miRNA expression levels differ between inflammatory and non-inflammatory regions of the 
ascending colon  
 We compared the changes in mucosal miRNA expression profiles between the inflammatory and 
non-inflammatory regions of the ascending colon. Expression and cluster analyses of miRNAs with 
significant differences revealed differences between the two sample groups. Among the miRNAs 
differentially expressed in the inflammatory versus non-inflammatory areas, 73 were upregulated and 
27 were downregulated (Figure 1B, Figure 4A-B). 
mRNA expression profiles of the inflammatory ascending colon in CD patients differ from 
healthy controls  
 Among the 36,333 probes (NimbleGen HG 18.0), 3,370 genes demonstrated significant 
differences between the HC and iCD groups (Log2FC absolute values > 1 and adjusted P-value < 
0.05), of which 2,169 were upregulated and 1,201 were downregulated in the iCD group compared to 
the HC group. The pathways associated with the differentially up- and downregulated genes, and 
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genes involved in each pathway are listed in Tables S3 and S4; more signalling pathways were 
associated with the upregulated genes than the downregulated genes. Pathways of upregulated genes 
closely related to CD pathology mainly included antigen processing and presentation, pathogenic 
Escherichia coli infection, cytokine-cytokine receptor interaction, and intestinal immune network for 
IgA production. Pathways of downregulated genes closely related to CD pathology mainly included 
the Hedgehog signalling pathway, pathways in cancer, natural killer cell-mediated cytotoxicity, and 
the mTOR signalling pathway.  
 We observed that inflammatory factors and cytokines related to immune functions were 
dysregulated in the inflammatory ascending colon of CD patients. Among them, IL1RL2, IL17, IL13, 
and IL22RA2 showed varying degrees of downregulation in inflammatory tissues, while IL-7R, IL1RB, 
IL6R, IL32, CXCL14, IL18BP, and CXCL5 showed varying degrees of upregulation (Figure 5D). 
mRNA and miRNA expression is correlated in the HC and iCD groups  
 We selected genes with high levels of expression in the inflammatory areas of CD patients and 
differentially expressed miRNAs to conduct correlation analyses of gene and miRNA expression 
(Log2 expression). We found that REG4, PLA2G2A, HLA-DQB1 and CXCL5 were highly expressed 
in the inflammatory areas of CD patients compared with HC (Log2FC values = 6.76, 5.81, 3.87, and 
2.58, respectively), and these genes highly correlated (r
2
 > 0.97) with different miRNAs. For example, 
there were positive correlations between REG4 and miR-21 (r
2
 = 0.9991, Figure S3A) and between 
PLA2G2A and miR-126 (r
2
 = 0.9996, Figure S3C). Conversely, there were negative correlations 
between CXCL5 and let-7i (r
2
 = 0.9943, Figure S3B) and between HLA-DQB1 and miR-106b* (r
2
 = 
0.9706, Figure S3D). 
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Quantitative real-time PCR validation 
 We chose three miRNAs (let-7a, let-7i, and miR-21) that were upregulated in the iCD group 
(another 7 patients) compared with healthy controls (another 7 individuals) as well as three 
downregulated miRNAs (miR-491-3p, miR-106b* and let-7d*) to be validated via qRT-PCR. The 
microarray results are shown in Figure 2B. The expression levels of let-7a, let-7i, and miR-21 were 
significantly increased in inflammatory areas of CD patients by 4.25, 2.5, and 2.68-fold, respectively, 
(Figure 5A); those of miR-491-3p, miR-106b*, and let-7d* were significantly reduced in the 
inflammatory areas of CD patients by 0.33, 0.53 and 0.44-fold, respectively (Figure 5C). We also 
verified the expression of LIMK1, TBKBP1, and TMEM30B in healthy control samples and those 
from inflammatory areas of CD patients. The results showed that, compared with the HC group, the 
expression levels of LIMK1 and TBKBP1 were reduced in the inflammatory areas of CD by 0.50 and 
0.33-fold, respectively, while that of TMEM30B was upregulated in the inflammatory areas of CD by 
4.02-fold; these differences were all significant (Figure 5B). 
 C10orf54 is a potential target gene of miR-16-1  
 Compared with the negative control group, the luciferase assay results of wild-type C10orf54 and 
SON suggested that miR-16-1 reduced expression by 37% (P = 0.004) and 20% (P = 0.014), 
respectively, suggesting that miR-16-1 could bind to the 3’UTR-1 of these target genes and inhibit 
their expression. Compared with the corresponding wild-type control groups, the luciferase assay 
results of the C10orf54 and SON mutant 3’UTR constructs demonstrated that miR-16-1 led to an 
increase of 23% (P = 0.005) and a decrease of 3%, respectively. These data indicate that miR-16-1 
cannot bind to the mutated C10orf54 3’UTR and thus cannot inhibit its expression (Figure 6B). We 
  
This article is protected by copyright. All rights reserved. 
therefore concluded that miR-16-1 can directly target the 3’UTR-1 region of the C10orf54 target gene 
to suppress its expression. We further observed a negative correlation between miR-16 expression and 
the mRNA expression level of C10orf54 (r
2
 = 0.7126, Figure 6A). 
 We also investigated the effects of miR-142-3p on the luciferase activities of its predicted target 
genes ATG16L1 and VPS24. Compared with the negative control group, the luciferase activity results 
showed reductions in the expression levels of wild-type ATG16L1 and VPS24 of 10% (P = 0.029) and 
17% (P = 0.031), respectively, suggesting that miR-142-3p can bind to the 3’UTR-1 of these target 
genes and inhibit their expression. Compared with the corresponding wild-type groups, luciferase 
activity test results of the mutants increased the expression levels of ATG16L1 and VPS24 by 11% 
and 10% in the presence of miR-142-3p; however, these differences were not significant, suggesting 
that miR-142-3p has weak binding capacities with ATG16L1 and VPS24, through which it can inhibit 
their expression (Figure S2). 
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Discussion 
 To our knowledge, the present study is the first to investigate miRNA expression profiles in the 
ascending colon mucosae of patients with active CD from the perspective of inflammatory and 
non-inflammatory tissues. Our results show that inflammatory and non-inflammatory regions of 
ascending colon mucosae have unique miRNA expression profiles. miRNAs are involved in various 
biological processes, such as cell differentiation and proliferation, apoptosis, and autophagy, and are 
closely related to the inflammation-mediated condition of CD 
22, 23
. 
 Previous studies have reported the miRNA expression profiles of inflammatory and 
non-inflammatory colonic mucosa, of colonic mucosa in active and inactive disease phases, and of 
peripheral blood 
13, 16
. Although some immune-related miRNAs have similar expression profiles, most 
miRNAs have unique expression patterns 
24, 25
. Previously, using healthy volunteers as controls, we 
compared the miRNA expression profiles in the mucosae of five sigmoid colon samples affected by 
CD and six ileum samples affected with CD. Microarray analysis determined that three miRNAs 
(miR-106a, miR-23b, and miR-191) were highly expressed and two miRNAs (miR-19b and miR-629) 
were downregulated in the sigmoid colon samples afflicted with CD, while four miRNAs (miR-16, 
miR-21, miR-223, and miR-594) were upregulated and no miRNAs were downregulated in the 
inflamed ileum 
16
. In addition, it has been found that miR-495-5p is downregulated in the 
inflammatory terminal ileum of CD patients, while miR-361-3p was upregulated and let-7b-5p was 
downregulated in the non-inflammatory terminal ileum 
15
. Previous studies in paediatric IBD patients 
investigated miRNA expression profile changes in the rectum and serum and identified three miRNAs 
(miR-192, miR-142-3p, miR-21) with significantly upregulated expression 
17
. In a study that did not 
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distinguish specific areas of the colon, CD patients with colonic inflammation expressed five 
upregulated miRNAs (miR-9, miR-126, miR-130a, miR-181C, and miR-375) compared to healthy 
volunteers, while four miRNAs (miR-9*, miR-30a*, miR-30c, and miR-223) were upregulated in 
non-inflammatory colonic mucosae 
26
. The miRNA expression profiles of peripheral blood from two 
adult CD patients showed significant upregulation of miR-199a-5p, miR-362-3p, and miR-532-3p. In 
another study, miR-16, miR-23a, miR-29a, miR-106a, miR-107, miR-126, miR-191, and miR-200c 
were upregulated, while in another study, miR-340* and miRplus-E1271 were upregulated 
13, 27
. The 
differentially expressed miRNAs identified from these studies are not exactly the same, which may be 
due to differing factors such as sample size, CD patient characteristics (age, drug history, with or 
without surgery, etc.), and subject population demographics (nationality, race) 
15
. Although the 
ascending colon is a site frequently affected by CD, until now, no studies have focused on the miRNA 
expression profiles of inflammatory and non-inflammatory regions of ascending colon mucosae in CD 
patients. 
 In our study, we found that hsa-miR-16, hsa-miR-21, and hsa-miR-223 expression levels were 
increased in the inflammatory ascending colon mucosa, and the results are similar to the expression 
patterns in inflammatory ileal mucosa 
16
, while showing significant differences from inflammatory 
sigmoid colon mucosa. miR-21 is closely related to myocardial fibrosis, and miR-146b is associated 
with ischaemia and hypoxia 
28
. In addition, miR-144, miR-451, miR-31, and miR-142-3p, which were 
also upregulated in inflammatory colonic mucosa, demonstrated significant differences in expression 
between the inflammatory ascending colon mucosa of active CD patients and healthy controls (Log2 
FC > 2.6, Figure 1C). Among these, miR-31 has been closely related to inflammation-related colon 
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cancer, is dynamically changed 
29
, and can act on target genes such as SNAIL, TWIST2, and ZEB1 
30
. 
It has been reported that expression of the miR-29 family is reduced in colonic mucosa associated 
with small intestinal narrowing; miR-29b inhibits TGF-β-induced intestinal fibrosis in CD patients 31, 
32
 and can directly regulate collagen genes (COL1, COL3, and COL4) 
33
. Interestingly, the 
expression levels of miR-32*, miR-106b*, and let-7d* were reduced in the inflammatory tissues 
compared to healthy controls and increased compared to the non-inflammatory tissue of the CD 
ascending colon. Let-7 is involved in the regulation of immune inflammation by regulating the 
activity of NF-κB and mediating the downregulation of IL-6 in macrophages 34.  
 We analysed the coexpression of miRNAs and mRNAs in the inflammatory ascending colon 
mucosae of CD patients and in the ascending colon mucosae of healthy volunteers. CXCL5, 14 and 16, 
and IL-13, 17, and 32 as well as other chemokines and cytokines closely related to inflammation were 
all upregulated at sites of colon inflammation (Figure 5D). Among these, CXCL5 and let-7i were 
negatively correlated (Figure S3B). CXCL14, CXCL5 and IL-17 are all highly expressed in 
inflammatory tissues and have demonstrated hypermethylation in UC but not CD patients. This 
feature might be used as a diagnostic marker for these two diseases 
35
. During the inflammation phase 
of IBD, the number of Th17 cells is increased, while IL-13, IL-17, and CXCL5 are all upregulated, 
suggesting that IL-13, IL-17, and CXCL5 are closely related to the pathology of enteritis and act 
closely with the PI3K-AKT signalling pathway 
36, 37
. IL-32 is a newly discovered proinflammatory 
cytokine that can activate the P38 and NF-κB signalling pathways to play a role in the immune 
response of IBD, but its specific roles with other proteins are still to be elucidated 
38
. It has been 
reported that DUOX2 and DUOXA2 are upregulated and closely related to inflammation in active UC. 
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In our study, compared with healthy volunteers, DUOX2 was upregulated in inflammatory ascending 
colon mucosae of CD patients 
39
, whereas DUOXA2 did not show significant differences. DUOX2 is 
an NADPH oxidase homologue and can release hydrogen peroxide. Another NADPH oxidase 
homologue, NOX1, also showed increased expression in iCD. Mesalazine therapy in UC patients acts 
by inhibiting DUOX2-mediated production of hydrogen peroxide, thereby reducing ROS-induced 
intestinal mucosal damage 
39
. In addition, we observed that, in comparison with healthy volunteers, 
the pro-inflammatory cytokines demonstrating significant changes in the inflammatory ascending 
colon, such as REG4, PLA2G2A, and HLA-DQB1, were also abnormally regulated and significantly 
upregulated in other inflammatory tissues. REG4 is a gene involved in anti-microbial reactions, and 
its expression in the inflammatory CD ascending colon was increased 108-fold compared to that of 
the healthy human; this upregulation was positively correlated with miR-21 (Figure S3A). This result 
is consistent with previous studies showing that REG4 expression in CD was only upregulated in 
comparison with healthy volunteers, and there was no change between CD and UC patients 
40
. REG4 
is an important member of the regeneration gene family. It participates in the proliferation and 
differentiation of intestinal cells and plays an important role in the diagnosis of intestinal tumours. 
PLA2G2A is an α-defensin specifically expressed in Paneth cells, and its expression level can reflect 
the number of Paneth cells. Our results show that PLA2G2A was highly expressed in the ascending 
colon mucosae of CD patients (56-fold) and was positively correlated with miR-126 (Figure S3C), 
consistent with previous studies 
41
. The human leukocyte antigen (HLA) allelic polymorphism is 
closely related to the genetic susceptibility of Han people to CD. Our results suggest that HLA-DQB1 
was upregulated in the inflammatory ascending colon, while other members of the HLA gene family 
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showed varying degrees of increased expression (Supplementary Material), suggesting that patients 
have a greater risk of CD susceptibility; furthermore, the expression of these genes was negatively 
correlated with miR-106b* (Figure S3D). Based on the prediction of miRNA target genes, we 
calculated the relevance and selected miRNAs and target genes for luciferase reporter gene assays. 
We discovered that miR-16-1 mimics could directly act on the 3'UTR of the wild-type C10orf54, 
inhibiting its expression. However, the inhibitory effect of the miR-16-1 mimics disappeared 
following mutation of the C10orf54 3’UTR (Figure 6B), and the two were negatively correlated. 
Upregulation of miR-16 in the inflammatory areas of the ascending colon mucosa probably inhibits 
the expression of C10orf54, which in turn causes immune inflammatory responses in the ascending 
colon, and reduction in miR-16 expression suggests the possibility of canceration of the inflammatory 
colon 
42
. miR-142-3p can act on the autophagy-related CD-susceptibility gene ATG16L1 in the CD 
ascending colon and play a regulatory role in colonic epithelial autophagy 
43
.  
We selected a number of miRNAs and validated these miRNAs via qRT-PCR. Compared with 
healthy volunteers, the expression levels of miR-21, let-7a, and let-7i were significantly upregulated 
in the inflammatory ascending colon mucosae of adult L2B1 CD patients, while those of miR-491-3p, 
miR-106b*, and let-7d* were significantly reduced. We also verified the expression of mRNAs and 
found that TMEM30B was significantly upregulated (four-fold) while LMK1 and TBKBP were 
significantly reduced. 
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 In summary, our data suggest that dysregulation of miRNA expression is mainly restricted to the 
inflammatory ascending colon mucosa of adult L2B1 CD patients: there are no obvious changes in 
non-inflammatory ascending colon mucosa, and the characteristics of the different miRNA expression 
profiles can be used to distinguish whether there is inflammatory infiltration in the colon.  
The main limitation is that the differences in the miRNA expression profiles between 
inflammatory and non-inflammatory ascending colon mucosae may be due to the different cell types 
collected via biopsy. In addition, the degree of inflammatory infiltration may affect miRNA 
expression in the inflammatory ascending colon mucosa. It will be important that the relationship 
between miRNAs and immune inflammation warrants further investigation. 
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Figure 1 Expression characteristics of miRNAs with differential expression in the ascending colon 
of CD patients. (A) Biopsy samples from CD patients were all from the ascending colon. (B) Venn 
diagram with red representing the number of miRNAs differing between iCD and HC; green 
representing the number of miRNAs differing between niCD and HC; and blue representing the 
number of miRNAs differing between iCD and niCD. (C) Respective expression of four miRNAs 
significantly upregulated in iCD compared with HC. (D) Respective expression of four miRNAs 
significantly downregulated in iCD compared with HC. 
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Figure 2 Different miRNA expression profiles between iCD and HC. (A) Heat map with intuitive 
reflection of the features of expression profile changes in the iCD and HC groups. (B) miRNAs 
up- or downregulated in iCD versus HC samples (absolute value log2FC ≥ 1, p < 0.05). 
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Figure 3 Different miRNA expression profiles between niCD and HC samples. (A) Heat map with 
intuitive reflection of the features of expression profile changes in the niCD and HC groups. (B) 
miRNAs up- or downregulated in niCD compared to HC (absolute value log2FC ≥ 1, p < 0.05). 
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Figure 4 The expression profiles of miRNAs differing between iCD and niCD. (A) Heat map with 
intuitive reflection of the features of expression profile changes in the iCD and niCD groups. (B) 
Up- and downregulated miRNAs comparing iCD to niCD (absolute value log2FC ≥ 1, p < 0.05). 
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Figure 5 qRT-PCR validation of miRNAs and mRNAs in iCD and HC ascending colon mucosae (A) 
miRNAs upregulated in iCD compared to HC; (B) genes differentially expressed between iCD and 
HC; (C) miRNAs downregulated in iCD compared to HC; (D) iCD/HC log2FC ratios of 
inflammatory cytokines. 
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Figure 6 Correlation between C10orf54 and miR-16 expression and luciferase reporter gene 
assay results. (A) C10orf54 and miR-16 are negatively correlated; (B) hsa-miR-16-1 inhibits 
wild-type (WT) C10orf54 expression and not mutant C10orf54 (MU) expression. 
